RxDoctor Payments Data

Daljit Singh, MD

Internal Medicine · Pittsburgh, PANPI 1952364044

Payments from drug & device makers

$35,329in general payments, 2019–2025

Across 1,993 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • Johnson & Johnson$4K
  • AbbVie$3K
  • GSK$3K
  • AstraZeneca$3K
  • Amgen$3K
  • plus $16K from 54 others

What the payments were for

  • Food & beverage$35,199100%
  • Education$1310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk281$4,229
Johnson & Johnson147$3,676
AbbVie(2 entities)175$3,214
GSK153$2,891
AstraZeneca140$2,849
Amgen(2 entities)168$2,653
Boehringer Ingelheim136$2,490
Lilly USA, LLC133$2,161
Novartis73$1,184
Merck74$1,079
Avanir Pharmaceuticals, Inc.54$1,053
Astellas Pharma US Inc34$664
Daiichi Sankyo Inc.28$606
Pfizer43$583
Amarin Pharma, Inc.33$583
Shield Therapeutics Inc29$547
Bayer32$497
E.r. Squibb & Sons, L.L.C.25$374
Otsuka America Pharmaceutical, Inc.9$263
Azurity Pharmaceuticals, Inc.19$243
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$241
Exact Sciences14$227
Kowa Pharmaceuticals America, Inc.15$223
Arbor Pharmaceuticals, Inc.13$216
Phathom Pharmaceuticals, Inc.14$216
Sanofi-aventis U.S. LLC10$185
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)15$176
Lundbeck LLC10$173
Esperion Therapeutics, Inc.7$155
Dexcom, Inc.8$153
Amneal Pharmaceuticals LLC8$151
Abbott8$125
UCB, Inc.5$107
Biohaven Pharmaceutical Holding Company Ltd.4$96
Scilex Pharmaceuticals Inc.5$90
Verona Pharma, Inc.4$75
Collegium Pharmaceutical, Inc.4$67
Takeda Pharmaceuticals U.S.A., Inc.4$65
Neurocrine Biosciences, Inc.4$63
Grifols USA, LLC3$63
Nestle Healthcare Nutrition Inc.3$51
Actelion Pharmaceuticals US, Inc.3$49
Paratek Pharmaceuticals, Inc.2$43
Almatica Pharma LLC2$37
Biohaven Pharmaceuticals, Inc.2$36
Ironwood Pharmaceuticals, Inc2$35
Indivior Inc.2$34
Philips North America LLC2$30
IBSA Pharma Inc.2$29
Xeris Pharmaceuticals, Inc.2$29
Alfasigma USA, Inc.2$27
Teva Pharmaceuticals USA, Inc.2$26
Supernus Pharmaceuticals, Inc.1$24
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$24
Axsome Therapeutics, Inc.1$22
Heartflow, Inc.1$20
Nabriva Therapeutics, PLC1$20
Valinor Pharma, LLC1$19
Phadia US Inc.1$16
Radius Health, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,329 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$453,754
Medicare patients
372
Services billed
4,750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban515$274,613
XareltoRivaroxaban331$221,293
MounjaroTirzepatide125$128,824
JardianceEmpagliflozin191$117,245
OzempicSemaglutide107$110,538
TradjentaLinagliptin123$75,026
Trijardy XrEmpaglifloz/Linaglip/Metformin74$54,406
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$54,281
FarxigaDapagliflozin Propanediol73$53,455
RybelsusSemaglutide34$42,408
ArexvyRsvpref3 Antigen/As01e/Pf146$42,024
MyrbetriqMirabegron83$38,148
GlatopaGlatiramer Acetate12$37,537
VraylarCariprazine Hcl21$35,063
EntrestoSacubitril/Valsartan51$28,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Spiriva Respimat, Glyxambi$2,490$283,966443 claims
PfizerEliquis$583$274,613515 claims
Johnson & JohnsonXarelto$3,676$221,293331 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$4,229$168,068153 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Anoro Ellipta$2,891$136,336316 claims
Lilly USA, LLCMounjaro$2,161$128,824125 claims
AbbVieVraylar, Linzess, Synthroid$3,214$64,686187 claims
AstraZenecaFarxiga$2,849$53,45573 claims
Astellas Pharma US IncMyrbetriq$664$38,14883 claims
NovartisEntresto$1,184$28,23251 claims
MerckJanuvia$1,079$26,12229 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$185$22,56023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →